Cristina Garcia
Research group
- Endocarditis. Cardiovascular infections. Experimental model Accredited researcher (R3A)
About me
Dr. Cristina García de la Mària is a researcher at IDIBAPS and has been the coordinator of the Experimental Endocarditis Laboratory for the last eighteen years. Together with the rest of the experimental endocarditis laboratory team, she conducts and carries out the in vitro and in vivo studies of the different models described in the group's lines of research. It is also responsible for the direction and training in the laboratory of master's and predoctoral students as well as researchers on postdoctoral stays. She has published 68 articles in peer review journals and coordinates the Work in Progress and Journal Club weekly sessions of the Endocarditis Team.
Featured publications
-
Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report
Authors:Reference: Journal Of Antimicrobial Chemotherapy 2019. -
AUC/MIC Pharmacodynamic Target Is Not a Good Predictor of Vancomycin Efficacy in Methicillin-Resistant Staphylococcus aureus Experimental Endocarditis.
Authors:Reference: Antimicrobial Agents And Chemotherapy 2017. -
Influence of Vancomycin Minimum Inhibitory Concentration on the Outcome of Methicillin-Susceptible Staphylococcus aureus Left-Sided Infective Endocarditis Treated with Anti-staphylococcal Beta-Lactam Antibiotics; a Prospective Cohort Study by the International Collaboration on Endocarditis.
Authors:Reference: Clinical Microbiology And Infection 2017. -
Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.
Authors:Reference: Journal Of Antimicrobial Chemotherapy 2017. -
Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.
Authors:Reference: Antimicrobial Agents And Chemotherapy 2017. -
Fosfomycin plus beta-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus
Authors:Reference: Antimicrobial Agents And Chemotherapy 2016.
Featured Projects
-
Prevention of vascular catheter-related infections by the FUNctionalization of CATHeters with thermically activated hydrogels with antimicrobial agents of broad spectrum (FUNCATH).
Principal investigator: Cristina Garcia de la MariaFunder: Fundació La Marató de TV3Code: 75/C/2018Duration: 15/01/2019 - 31/12/2022 -
In vitro and experimental endocarditis model study of the efficacy of new oral and parenteral combinations of antibiotics for outpatient treatment of infectious endocarditis
Principal investigator: José Maria Miró MedaFunder: ISCIII (Participante)Code: PI 20/00830Duration: 01/01/2021 -
Staphylococcus aureus sensitivity to CF-301 Lysin in an in vitro study by Broth Microdilution Method.
Principal investigator: Josep M. Miró MedaFunder: ContraFect CorporationDuration: 01/03/2019 -
Estudio de la eficacia de daptomicina asociada a otros antibióticos en el tratamiento de la endocarditis experimental por Staphylococcus aureus resistente o no a meticilina (SARM/SASM) y Staphylococcus epidermidis resistentes a meticilina (SERM) y a vancomicina (VRSE)
Principal investigator: Jose Maria Miro MedaFunder: Fundació Privada Clínic per a la Recerca Biomèdica (Sede o evento); Instituto de Salud Carlos IIIDuration: 01/01/2011 - 31/12/2013 -
To evaluate wether the combination of gentamicin and daptomycin (at doses of 6 mg/ kg or 10 mg/Kg) prevents the development of daptomycin resistance in the treatment of experimental endocarditis in rabbits infected with a penicillin-resistant Streptococcus mitis strain that develops a high level of daptomycin resistance when daptomycin is given in monotherapy.
Principal investigator: Jose Maria Miro MedaFunder: Cubist Pharmaceutical ; Fundació Privada Clínic per a la Recerca Biomèdica (Participante)Duration: 01/01/2011